- Trial Phase
- Approved in China (3 indications); global Phase 3 readout pending
- Time to Market
- Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
- Why 6/10
- The next hard, dated binary is the SAFFRON global Phase 3 (savolitinib + osimertinib) topline readout that HUTCHMED guides to H2 2026 (roughly 4-6 months out), plus a China Phase 3 savolitinib+osimertinib trial (NCT05009836, 320 patients) with estimated primary completion 2026-08-30 — a pivotal readout within ~6 months on a major (but not the only) program at a multi-product company, so 6 rather than higher.
Watch for SAFFRON/SANOVO Phase 3 topline data in H2 2026 — a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
Price Chart
Executive Summary
ORPATHYS (savolitinib), a MET-targeting cancer pill developed by HUTCHMED (HCM) with partner AstraZeneca, is already a commercial product in China: it holds three NMPA approvals (MET-mutated lung cancer; and as of July 2026, MET-amplified gastric cancer) and is on China's National Reimbursement Drug List. The near-term investor question is not the drug's validity but its next-stage growth: HUTCHMED's H1 2026 results guide SAFFRON (global) and SANOVO (China) Phase 3 topline readouts to H2 2026, which would unlock ex-China filings. Analyst consensus is strongly positive (23 buy/strong-buy vs 3 hold, mean target $21.77 vs $11.13), but the stock sits near its 52-week low and the pending pivotal readout is a genuine two-sided binary.
How It Works
Savolitinib is a daily pill that blocks MET, a protein 'on-switch' some cancers use to grow and spread. It targets lung and stomach cancers where MET is overactive — either mutated (MET exon 14 'skipping') or amplified (extra gene copies) — and is often combined with the EGFR pill osimertinib to treat lung cancers that develop MET-driven resistance to EGFR therapy.
Trial Status
Commercially launched in China with AstraZeneca; third NMPA approval (conditional) for MET-amplified gastric cancer announced July 2, 2026, based on a pivotal Phase 2 (NCT04923932, 110 patients, completed Apr 2026): 32.3% ORR, 4.0-month median PFS. Two Phase 3 savolitinib+osimertinib NSCLC trials tracked: NCT05009836 (ACTIVE_NOT_RECRUITING, est. primary completion 2026-08-30, 320 pts) and NCT05015608 (completed; 216 pts). Company guides SAFFRON (global) and SANOVO (China) Phase 3 toplines for H2 2026.
The Two-Sided Case
Upcoming Catalysts
- SAFFRON global Phase 3 (savolitinib+osimertinib) topline — company-guided H2 2026
- SANOVO China Phase 3 topline — company-guided H2 2026
- Phase 3 NCT05009836 (savolitinib+osimertinib, EGFRm+/MET+ NSCLC, 320 pts) estimated primary completion 2026-08-30
- Pending disclosure of Phase 2 gastric cancer (NCT04923932) final results and any post-marketing confirmatory study updates
- H2 2026 financial results (sales trajectory of ORPATHYS across 3 indications)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
HUTCHMED (China) Ltd 6-K HCM ·Originating report